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A B S T R A C T
Surgical valve replacement is the definitive therapy for patients with critical aortic ste-
nosis (AS). However, the risk of surgery may be higher in elderly patients with signifi-
cant comorbidities. Six years after the first in man, percutaneous aortic valve implan-
tation (PAVI) for the treatment of AS currently represents a dynamic field of research 
and development. Two devices have a CE marked and are under clinical investigation 
for PAVI, the Edwards-Sapien valve mounted within a balloon-expandable stent and 
the self-expanding CoreValve. Since the first in-man PAVI by Alain Cribier in 2002, 
well over 1000 high-risk patients with severe symptomatic AS have been treated using 
PAVI (as of January 2008). The currently available results suggest that the technique 
is feasible and provides hemodynamic and clinical improvement for up to two years 
in patients with critical AS at high risk or with contraindications for surgery. Pending 
questions concern mainly safety and long-term durability.
I N T R O D U C T I O N
Valve disease is an important public health problem as it carries a poor prognosis 
and its prevalence is strongly linked to the phenomenon of population ageing. The most 
frequent native valve disease in Europe is currently aortic stenosis (AS), which is most 
often seen in elderly patients with comorbidities. Valve replacement is the definitive 
therapy for patients with severe AS who have symptoms or objective consequences 
such as left ventricular (LV) dysfunction.1 Operative mortality is quite low, even in 
elderly patients when properly selected, and long-term results have been shown to 
be satisfactory. However, the risk of surgery may be higher in elderly patients with 
significant comorbidities. In addition, several registries show that referring physicians 
often do not propose surgery, as was the case in the Euro Heart Survey with 33% of 
patients with severe valve disease and severe symptoms not being considered for sur-
gery.2 Thus, despite the good results of valve surgery there may well be a role for less 
invasive alternatives. Balloon aortic valvuloplasty (BAV) is now rarely used, mainly 
due to its limited long-term efficacy.
Six years after the first in man,3 percutaneous aortic valve implantation (PAVI) for 
the treatment of AS currently represents a dynamic field of research and development: 
two devices have been CE marked and are being commercialised.4-8 These two devices 
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are under clinical investigation for PAVI. One device is the 
Edwards-Sapien valve (Edwards Lifesciences Inc, California, 
USA), which consists of 3 pericardial leaflets mounted within 
a tubular, slotted, stainless-steel, balloon-expandable stent. 
The other device is the CoreValve Revalving System (CRS 
TM, CoreValve Inc, Irvine, California, USA), which has 3 
pericardial leaflets, initially bovine and currently porcine, 
mounted in a self-expanding, nitinol frame. Since the first 
in-man PAVI by Alain Cribier in 2002,3 well over 1000 high-
risk patients with severe symptomatic AS have been treated 
using PAVI (as of January 2008).
T R A N S F E M O R A L  A P P R O A C H
Over 400 cases have been performed using the balloon ex-
pandable and another 500 using the self-expandable prosthesis 
(Company sources January 2008). Reports originate from a 
number of centres worldwide.4-7 The patients treated were 
mostly over 80 years old, at high risk (e.g. Logistic EuroScore 
>20% in most cases), or with contraindications for surgery.
The overall results can be summarised as follows:
Procedural success is closely linked to experience, and is 
about 90% in experienced centres. A learning curve can also 
be observed resulting in better patient selection and outcomes. 
Valve function is good with a final valve area ranging from 
1.5 to 1.8 cm².
Mortality at 30 days ranges from 5 to 18%. Acute myo-
cardial infarction occurs in 2 to 11%. Coronary obstruction 
is rare (<1%). Mild to moderate aortic regurgitation, mostly 
paravalvular, is observed in around 50% of cases. However, 
the availability of larger prostheses and their more careful 
matching with the size of the aortic annulus led to the decrease 
in the incidence of severe aortic regurgitation to around 5%. 
Prosthesis embolization is rare, around 1%.
Vascular complications, with an incidence ranging from 10 
to 15%, remain a significant cause of mortality and morbidity. 
Stroke ranges from 3 to 9%. Finally, atrioventricular block 
occurs in 4 to 8%, necessitating pacemaker implantation in 
up to 24% with self-expandable devices.
Long-term results up to 2 years (though only 1 year in most 
studies) are reported in a limited number of patients. They 
show a survival rate of 70-80% with a significant improvement 
in clinical condition in most cases. The majority of late deaths 
are due to comorbidities. Serial echocardiographic studies 
have consistently shown good prosthetic valve function with 
no structural deterioration of valve tissue.
T R A N S A P I C A L  A P P R O A C H
The total experience with transapical aortic valve implan-
tation9,10 comprises over 300 patients, also at high risk for 
conventional surgery, even more so because of concomitant 
peripheral arterial disease, in most cases. Experience currently 
reported only relates to the balloon-expandable prosthesis.
The implantation success rate of the transapical proce-
dure is around 90%. Over 70% of cases are done off pump, 
the figure being 90% in experienced centres, and the rate of 
peri-operative conversion is 9-12%. Mortality rates range from 
9-18%. The incidence of stroke is 0-6%. The quality of the 
results seems closely related to experience as well as to the 
availability of high quality imaging in the operating theatre. 
There are currently no direct comparative studies available 
of the two approaches.
P E R S P E C T I V E S
Progress in delivery systems and valve manufacturing 
could lead to lower-profile, repositionable, retrievable, and 
more durable devices, as well as a wider range prosthetic 
valve dimensions. Furthermore, improved imaging, such as 
online 3D reconstruction and stereotaxis, could facilitate 
valve placement.
P E N D I N G  Q U E S T I O N S
In the light of the current experience, bearing in mind the 
previously-mentioned, inherent limitations of any conclusions, 
PAVI using both balloon and self-expandable devices can be 
said to be feasible. Short- and mid-term hemodynamic results 
are good up to two years. However, the technique remains 
challenging, in particular, with regards to vascular access, 
device sizing, and positioning.
The major concerns with regards to safety are:
Vascular complications with the transfemoral approach, 
which should decrease with smaller devices.
Stroke rate.
Long-term consequences of paravalvular leaks, even if 
mild to moderate regurgitation is considered not to have 
significant clinical consequences in the short-term.
Atrioventricular block, the incidence, timing, and predic-
tors of which have to be identified more precisely.
Mid- (short-) term clinical outcome is encouraging; how-
ever, long-term durability of these bioprostheses remains a 
key question, especially if considering lowering the threshold 
for the indication.
The feasibility of subsequent aortic valve intervention is 
not known.
Selection of candidates for PAVI, especially risk assess-
ment, should involve multi-disciplinary consultation between 
cardiologists and surgeons.
PAVI is indicated in patients with calcified pure or pre-
dominant aortic stenosis. At the present stage, PAVI should 
only be proposed in patients with severe symptoms that can 
definitely be attributed to valve disease. The procedure should 
currently be restricted to patients at high-risk or with contrain-
dications for surgery. It is premature to consider using it in 
patients who are good surgical candidates. PAVI should not 
be performed in patients whose life expectancy is less than 1 
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year, who should be managed conservatively.
General contraindications for PAVI are:
Aortic annulus <18 mm or >25 mm for balloon expand-
able and <20 or >27 for self expandable devices.
Bicuspid valves because of the risk of incomplete deploy-
ment of the stented valve.
Presence of asymmetric heavy valvular calcification, which 
may compress the coronary arteries during PAVI. The 
risk of coronary compression can be anticipated during 
BAV.
Presence of bulky atherosclerosis of the ascending aorta 
and arch detected by TEE.
Aortic root dimension >45 mm at the aorto-tubular junc-
tion for self-expandable prostheses.
Presence of apical LV thrombus.
The performance of PAVI, even more so ab initio, should 
be restricted to a limited number of high volume centres, 
which have both cardiology and cardiac surgery departments. 
The procedure requires the close cooperation of a team of 
specialists in valve disease including clinical cardiologists, 
echocardiographers,11 interventional cardiologists, cardiac 
surgeons and anaesthesiologists.8 A hybrid suite is ideal as it 
fulfils the role of both an operating room and a catheteriza-
tion laboratory.
The currently available results obtained with PAVI suggest 
that these techniques are feasible and provide hemodynamic 
and clinical improvement for up to two years in patients with 
severe symptomatic AS at high risk or with contraindications 
for surgery. Pending questions concern mainly safety and 
long-term durability. Surgeons and cardiologists must work as 
a team to select the best candidates, perform the procedure, 
and, finally, evaluate the results. Today these techniques are 
targeted at high-risk patients but they may be extended to 
the lower risk group in the future, if the initial promise holds 
true after careful evaluation. We are currently at the stage of 
evaluation, and a careful commercialisation process including 
training and post-market surveillance is crucial to avoid the 
risk of uncontrolled diffusion.
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